Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer

Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer

Publication date: Feb 04, 2019

A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies, who are ineligible for or there are no available therapies known to confer a clinical benefit for their disease, or they have exhausted all such available options in each indication and therefore will be patients for whom a clinical trial is appropriate.



Please signin to view all article content and metadata.


Leave a Comment

Your email address will not be published. Required fields are marked *